AU2022396530A1 - Methods of treating neurological disorders - Google Patents
Methods of treating neurological disorders Download PDFInfo
- Publication number
- AU2022396530A1 AU2022396530A1 AU2022396530A AU2022396530A AU2022396530A1 AU 2022396530 A1 AU2022396530 A1 AU 2022396530A1 AU 2022396530 A AU2022396530 A AU 2022396530A AU 2022396530 A AU2022396530 A AU 2022396530A AU 2022396530 A1 AU2022396530 A1 AU 2022396530A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- fesoterodine
- administered
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283140P | 2021-11-24 | 2021-11-24 | |
| US63/283,140 | 2021-11-24 | ||
| US202263416745P | 2022-10-17 | 2022-10-17 | |
| US63/416,745 | 2022-10-17 | ||
| PCT/US2022/080429 WO2023097276A1 (en) | 2021-11-24 | 2022-11-23 | Methods of treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022396530A1 true AU2022396530A1 (en) | 2024-06-13 |
Family
ID=86540399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022396530A Pending AU2022396530A1 (en) | 2021-11-24 | 2022-11-23 | Methods of treating neurological disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250032460A1 (https=) |
| EP (1) | EP4436564A4 (https=) |
| JP (1) | JP2024541770A (https=) |
| KR (1) | KR20240110642A (https=) |
| AU (1) | AU2022396530A1 (https=) |
| CA (1) | CA3239067A1 (https=) |
| IL (1) | IL313067A (https=) |
| MX (1) | MX2024006371A (https=) |
| WO (1) | WO2023097276A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3061821T (pt) * | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| US8853219B2 (en) * | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| CA2978214A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
-
2022
- 2022-11-23 MX MX2024006371A patent/MX2024006371A/es unknown
- 2022-11-23 AU AU2022396530A patent/AU2022396530A1/en active Pending
- 2022-11-23 IL IL313067A patent/IL313067A/en unknown
- 2022-11-23 JP JP2024531094A patent/JP2024541770A/ja active Pending
- 2022-11-23 US US18/712,916 patent/US20250032460A1/en active Pending
- 2022-11-23 CA CA3239067A patent/CA3239067A1/en active Pending
- 2022-11-23 EP EP22899553.6A patent/EP4436564A4/en active Pending
- 2022-11-23 WO PCT/US2022/080429 patent/WO2023097276A1/en not_active Ceased
- 2022-11-23 KR KR1020247020828A patent/KR20240110642A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3239067A1 (en) | 2023-06-01 |
| US20250032460A1 (en) | 2025-01-30 |
| JP2024541770A (ja) | 2024-11-12 |
| EP4436564A4 (en) | 2025-10-22 |
| EP4436564A1 (en) | 2024-10-02 |
| IL313067A (en) | 2024-07-01 |
| MX2024006371A (es) | 2024-07-15 |
| KR20240110642A (ko) | 2024-07-15 |
| WO2023097276A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9913836B2 (en) | Anticholinergic neuroprotective composition and methods | |
| EP3263108B1 (en) | Composition and method for treatment of depression and psychosis in humans | |
| US6228875B1 (en) | Methods for treating neuropsychiatric disorders | |
| US7718677B2 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2008056697A (ja) | Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物 | |
| WO2014052935A2 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| CN101822676A (zh) | 治疗运动疾病患者的方法 | |
| US20190015399A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| AU2016319107A1 (en) | Methods of treating neurodegenerative disorders in a particular patient population | |
| US20180110768A1 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| JP2014520856A (ja) | 併用ａｌｓ療法 | |
| US20250032460A1 (en) | Methods of treating neurological disorders | |
| US9066949B2 (en) | Compositions and methods for the treatment of catatonia | |
| US11318122B2 (en) | Pharmaceutical combination and its use for treating synucleinopathties | |
| CN118510500A (zh) | 治疗神经系统障碍的方法 | |
| CN1300217A (zh) | 瑞波西汀与吲哚洛尔的新的药物组合 | |
| EP4719383A2 (en) | Compositions for treating neurological disorders | |
| CN121868499A (zh) | 一种预防或治疗神经系统变性疾病的方法和药物组合 | |
| AU2011203482B2 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| AU2013263769A1 (en) | Paediatric compositions for treating multiple sclerosis | |
| HK1161108A (en) | Compositions of r(+) and s(-) pramipexole and methods for using the same | |
| AU2009259950A1 (en) | Paediatric compositions for treating1 multiple sclerosis |